Loading people...
Hadrien Bouchez is a Partner at Kurma Partners, a healthcare venture capital firm managing over €700 million in assets, based in Amsterdam, Netherlands. He joined the firm as an Analyst in 2014 after working at Evidence Bio, and holds a Doctor of Pharmacy from the University of Lille alongside a Master of Science in Entrepreneurship from ESSEC Business School. During his tenure, Bouchez has participated in more than a dozen life sciences investments through the firm's Biofund II and III vehicles. He contributed to the creation of several biotechnology startups, including Dynacure, Imcheck Therapeutics, and Flamingo Therapeutics, while currently serving as a board member for Ermium Therapeutics. His portfolio track record features notable acquisitions, such as the sale of Corlieve Therapeutics to uniQure and Emergence Therapeutics to Eli Lilly. Bouchez focuses on sourcing early-stage European therapeutics companies.
Hadrien Bouchez stands as a key figure at Kurma Partners, a prominent European venture capital firm dedicated to advancing innovation in the life sciences sector. As a Principal, Hadrien plays a crucial role in the firm's investment strategy, actively contributing to the identification, evaluation, and nurturing of groundbreaking companies that are poised to reshape healthcare. His work is central to Kurma Partners' mission of supporting visionary entrepreneurs and scientific breakthroughs.
At Kurma Partners, Hadrien Bouchez's responsibilities encompass a broad spectrum of activities vital to venture capital success. He is deeply involved in deal sourcing, meticulously scouting for promising early-stage and growth-stage companies across Europe. His expertise is critical in conducting rigorous due diligence, assessing the scientific merit, market potential, and team capabilities of prospective investments. Furthermore, Hadrien works closely with Kurma's portfolio companies, providing strategic guidance and operational support to help them navigate challenges and accelerate their development towards clinical and commercial milestones.
Hadrien's investment focus aligns with Kurma Partners' commitment to addressing significant unmet medical needs. He is particularly interested in innovative therapeutics, including novel biologics, small molecules, and gene therapies, that offer transformative potential for patients. Beyond drug development, his expertise extends to cutting-edge diagnostics, medical devices, and digital health solutions that enhance patient care, improve outcomes, and optimize healthcare delivery. He seeks out companies with strong intellectual property, robust scientific foundations, and clear pathways to market.
While specific details of Hadrien Bouchez's career background are not publicly detailed, individuals in his role typically possess a strong foundation in life sciences, often holding advanced scientific degrees combined with significant experience in finance, business development, or strategic consulting within the healthcare industry. This multidisciplinary background equips him with the unique ability to bridge the gap between scientific innovation and commercial viability, a critical skill in the competitive life sciences venture capital landscape. His contributions are integral to Kurma Partners' track record of backing successful ventures that bring novel treatments and technologies to patients worldwide.
Hadrien Bouchez's dedication to fostering innovation makes him an influential investor in the European life sciences ecosystem. His strategic insights and commitment to supporting pioneering companies underscore his impact at Kurma Partners, where he continues to drive investments that promise to deliver the next generation of healthcare solutions.
Hadrien Bouchez is a Principal at Kurma Partners, a leading European venture capital firm focused on life sciences investments. He is instrumental in identifying, evaluating, and supporting innovative biotech and medtech companies.
Hadrien Bouchez invests in a wide range of life sciences sectors, including innovative therapeutics (biologics, small molecules, gene therapies), diagnostics, medical devices, and digital health solutions that address significant unmet medical needs.
Hadrien Bouchez works at Kurma Partners, a prominent European venture capital firm specializing in life sciences investments. Kurma Partners has offices in Paris and Munich, focusing on the European healthcare innovation landscape.
